Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer : Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support

Abstract EN

The purpose of the study was to identify predictors of long-term survival in metastatic breast cancer (MBC).

A cohort of 96 patients, who received high-dose chemotherapy with autologous stem cell support (HD-ASCT) as part of their treatment, was analyzed.

Percent long-term survival at 10 years was 24.5% (CI 17.2–34.9%) when metastasis was diagnosed and 14.4% (CI 8.7–23.9%) when MBC was diagnosed.

Survival was impacted significantly by body mass index (BMI).

Median overall survival from initial diagnosis or from time of metastasis for patients with BMIs ≤30 and >30 (obese) was 7.1 (CI 4.4–8.7) and 3.2 years (2.41–6.75), respectively, or 3.2 or 2.3 years (all P=0.02).

Also, obesity was the only independent patient-related predictor of time to metastasis and of survival.

While obesity is linked with poor outcomes in earlier stages of breast cancer, this has not been previously reported for MBC.